Journal Mobile Options
Table of Contents
Vol. 72, No. 3-4, 2007
Issue release date: January 2008
Section title: Clinical Study
Oncology 2007;72:152–159
(DOI:10.1159/000112795)

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

Boone S.L. · Rademaker A. · Liu D. · Pfeiffer C. · Mauro D.J. · Lacouture M.E.
aDepartment of Dermatology, SERIES Clinic, bDepartment of Preventive Medicine, Northwestern University’s Feinberg School of Medicine, and cRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill., and dBristol-Myers Squibb, Plainsboro, N.J., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 6/26/2007
Accepted: 6/28/2007
Published online: 12/21/2007

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 5

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Biologic agents targeting the epidermal growth factor receptor (EGFR) have emerged as a robust treatment option for various solid tumors. Despite lower systemic side effects than conventional chemotherapy, the majority of patients treated with these agents experience cutaneous toxicities, including papulopustular rashes, hair and nail changes, xerosis and pruritus, which have a significant impact on health and quality of life. Currently no consensus or management guidelines exist for these untoward events. Therefore, a retrospective survey was carried out across 110 oncology practioners in the US that were administering EGFR inhibitors. Providers were queried on the impact and management of these untoward events in their practices. Responses suggest that combination therapies (topical and oral) were more effective than either therapy alone, and also lead to a more rapid resolution of the papulopustular rash. Providers also reported that patients frequently complained of physical symptoms associated with the rash (itching and pain), and that they had a positive perception when being treated for their cutaneous side effects. The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration.


  

Author Contacts

Mario E. Lacouture, MD
Department of Dermatology
Northwestern University’s Feinberg School of Medicine
676 N. St. Clair St., Suite 1600, Chicago, IL 60611 (USA)
Tel. +1 312 695 8106, Fax +1 312 695 0664, E-Mail m-lacouture@northwestern.edu

  

Article Information

Received: June 26, 2007
Accepted: June 28, 2007
Published online: December 21, 2007
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 5, Number of References : 34

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 72, No. 3-4, Year 2007 (Cover Date: January 2008)

Journal Editor: Markman, M. (Houston, Tex.)
ISSN: 0030–2414 (Print), eISSN: 1423–0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 6/26/2007
Accepted: 6/28/2007
Published online: 12/21/2007

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 5

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.